Henry Ford Hospital Medical Journal
Volume 11 | Number 4

Article 9

12-1963

A Note On The Absence Of Thyroid Stimulating
Hormones In Toxic Autonomous Goiter
J. Martin Miller
Melvin A. Block
Robert C. Horn

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health
Commons
Recommended Citation
Miller, J. Martin; Block, Melvin A.; and Horn, Robert C. (1963) "A Note On The Absence Of Thyroid Stimulating Hormones In Toxic
Autonomous Goiter," Henry Ford Hospital Medical Bulletin : Vol. 11 : No. 4 , 449-452.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol11/iss4/9

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry
Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact
acabrer4@hfhs.org.

Henry Ford Hosp. Med. Bull.
Vol. 11, December, 1963

A NOTE ON THE ABSENCE OF THYROID STIMULATING HORMONES
IN TOXIC AUTONOMOUS GOITER
J. M A R T I N M I L L E R , M.D.,* M E L V I N A. BLOCK, M . D . * *
AND ROBERT C . HORN, M . D . * * *

IMPROVED BIOASSAY for thyrotropic hormone (TSH) and long acting thyroid stimulator (LATS), has provided new support for the long held concept of the nonthyroidal origin of Graves' disease. The term "toxic dependent goiter", recently introduced for this condition, is an acknowledgment of our better understanding of
its pathophysiology.' Simultaneously, we have improved our knowledge of toxic
autonomous goiter, the hyperthyroidism first described by Plummer in 1913.^ One
form of this latter disease, the solitary toxic nodule, is easily identified by the 1-131
scintigram. Another form, that represented by conglomeration of many such nodules
is more difficult to diagnosis. This type of thyrotoxic patient has a large goiter which
antedates his disease, often with a generalized although patchy distribution of 1-131
on the scintigram. It has been suggested that such patients usually represent Graves'
disease super-imposed on an old multinodular goiter, the areas of lesser activity
representing tissue incapable of stimulation.^ This opinion has received support from
an assay for LATS done on an elderly patient whom McKenzie considered typical
of toxic nodular (autonomous) goiter." The assay was positive, although the same
teit was negative when performed on the serum of a patient with solitary toxic nodule.
The authors have recently hypothesized that many large goiters in thyrotoxic
patients represent the high end of the spectrum of toxic autonomous goiter. This
IS an old observation but one never proved using the investigative tools of the past
15 years. In an attempt to make this theory currently acceptable, three recent
patients with thyrotoxicosis and large goiters of long duration have been extensively
studied. The purpose of this report is to call attention to the results of the analyses
for TSH and LATS done on these patients. A l l were mild to moderately thyrotoxic,
gave a history of thirty to forty years of goiter, and complained primarily of the
cardiac manifestations of the disease. A l l had physical findings diagnostic of thyrotoxicosis and none had eye signs of any description or the neuromuscular excitabihty
characteristic of Graves' disease. A l l had an elevated protein-bound iodine but none
had an elevated 1-131 uptake. (The latter may have been influenced by the geometry
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involved in counting the large goiters.) The uptake in all was considerably increased
by the administration of 10 units of TSH. The laboratory findings are summarized
in Table 1.
Table 1
Case

Age

Thyroid
Weight

PBI

24 hour 1-131
Uptake

Uptake after
TSH

LATS

TSH

1

58

195 gm.

14.2

20%

65%

neg.

neg.

2

75

240 gm.

1 1.2

35%

70%*

neg.

neg.

3

61

340 gm.

9.6

22%

65%**

neg.

neg.

* Estimated from 24 hour urinary excretion of 15%.
**Estimated from 24 hour urinary excretion of 20%.

The appearance of the initial scintigram in each was somewhat dissimilar and
the post-TSH scintigram was also. In Figure 1 the scintigram from Case 1 shows
several areas of decreased uptake which do not change in B, the post-TSH scintigram.
In Case 2, (Figure 2) the effect of TSH is evident in that the hot area in the left
lower lobe has disappeared, that is, the surrounding tissue increased in uptake while
the hot area did not. It reappeared on a subsequent scintigram. The scintigram
of Case 3 (Figure 3) presents a more uniform generalized uptake than the other two,
but there is a suggestion of altered distribution of the more active areas after TSH.
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Figure 1
Scintigram of the thyroid, Case 1.
B. After TSH.
A. Before TSH.

Serum was withdrawn while the patients were still thyrotoxic, immediately frozen
and sent in this state to Bio-Science Laboratories, Los Angeles, California. TSH
and LATS were determined by Dr. Orville Golub using the mouse assay method
of McKenzie.* The serums of all three were reported as negative for both hormones.
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Figure 2
Scintigram of the thyroid. Case 2.
A. Before TSH.

B. After TSH.

Figure 3
Scintigram of the thyroid. Case 3.
A. Before TSH.

B. After TSH.
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Preparation for surgery consisted of methimazole, 100-125 mg. daily, for 2-3
months, and supportive adrenal steroid therapy beginning 12 hours pre-operatively.
The latter was continued for 48 hours postoperatively. Case 1 was also given iodides
for seven days as insurance against an incorrect diagnosis, even though previous
administration of iodides had been said to aggravate her cardiac condition. No
beneficial or detrimental effect was noted.
Extensive autoradiographic studies were done which will be the subject of later
reports, but neither these nor ordinary tissue sections from 13-17 blocks of tissue
per gland suggested Graves' disease. The histopathology did not differ essentially
from that of large nontoxic nodular goiters.
The entire clinical and laboratory picture, therefore is consistent with the concept
that this disease is similar in pathophysiology to the solitary toxic nodule, and distinct
from toxic dependent goiter, or Graves' disease. In these patients a large volume
of poorly functioning autonomous tissue eventually produces an unphysiologic amount
of thyroid hormone, and toxicity ensues. Pituitary TSH is suppressed, as verified by
the assay, and exogeneous TSH may stimulate uptake either in suppressed normal
tissue or in the autonomous tissue itself. The absence of LATS in the serum further
documents the autonomy of the thyroid in this disease. It is not suggested that all
large pre-existing goiters in thyrotoxic patients represent the same entity, for Graves'
disease may be superimposed on any stage of sporadic or endemic goiter.

SUMMARY

Three cases of toxic autonomous multinodular goiter are presented, none of
which had clinical or laboratory findings suggestive of Graves' disease. A l l had
negative serum assays for LATS and TSH. The absence of these hormones substantiates
the diagnosis made by more simple methods.
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